Vienna, Austria - New data presented this week has shown that the novel antianginal agent ranolazine (Ranexa, CV Therapeutics, Palo Alto, CA), an inhibitor of the late phase of the sodium current, is ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Patients with chronic angina and incomplete revascularization after PCI did not exhibit an ...
Ranolazine reduced episodes of stable angina in diabetes patients already receiving one or two antianginal drugs and led to less use of sublingual nitroglycerin, and the benefits appeared more ...
Pulmonary Circulation, Vol. 5, No. 4 (December 2015), pp. 691-700 (10 pages) AbstractPulmonary arterial hypertension (PAH) causes right ventricular ischemia, dysfunction, and failure. PAH patients may ...
heart ecg arrhythmia The pharmacological properties of ranolazine, as well as evidence from clinical trials, suggest it may be beneficial in patients with atrial fibrillation. The pharmacological ...
According to the results of a study reanalyzing data obtained from an FDA review, , ranolazine potentiates the effects associated with ACE inhibitors, as well as angiotensin receptor blockers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results